Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager
Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA
XBRU:HYL
Watchlist
Price: 4.29 EUR -6.94% Market Closed
Market Cap: 120.1m EUR
Have any thoughts about
Hyloris Pharmaceuticals SA?
Write Note

Intrinsic Value

The intrinsic value of one HYL stock under the Base Case scenario is 4.37 EUR. Compared to the current market price of 4.29 EUR, Hyloris Pharmaceuticals SA is Undervalued by 2%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HYL Intrinsic Value
4.37 EUR
Undervaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Hyloris Pharmaceuticals SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for HYL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about HYL?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Hyloris Pharmaceuticals SA

Provide an overview of the primary business activities
of Hyloris Pharmaceuticals SA.

What unique competitive advantages
does Hyloris Pharmaceuticals SA hold over its rivals?

What risks and challenges
does Hyloris Pharmaceuticals SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Hyloris Pharmaceuticals SA.

Provide P/S
for Hyloris Pharmaceuticals SA.

Provide P/E
for Hyloris Pharmaceuticals SA.

Provide P/OCF
for Hyloris Pharmaceuticals SA.

Provide P/FCFE
for Hyloris Pharmaceuticals SA.

Provide P/B
for Hyloris Pharmaceuticals SA.

Provide EV/S
for Hyloris Pharmaceuticals SA.

Provide EV/GP
for Hyloris Pharmaceuticals SA.

Provide EV/EBITDA
for Hyloris Pharmaceuticals SA.

Provide EV/EBIT
for Hyloris Pharmaceuticals SA.

Provide EV/OCF
for Hyloris Pharmaceuticals SA.

Provide EV/FCFF
for Hyloris Pharmaceuticals SA.

Provide EV/IC
for Hyloris Pharmaceuticals SA.

Show me price targets
for Hyloris Pharmaceuticals SA made by professional analysts.

What are the Revenue projections
for Hyloris Pharmaceuticals SA?

How accurate were the past Revenue estimates
for Hyloris Pharmaceuticals SA?

What are the Net Income projections
for Hyloris Pharmaceuticals SA?

How accurate were the past Net Income estimates
for Hyloris Pharmaceuticals SA?

What are the EPS projections
for Hyloris Pharmaceuticals SA?

How accurate were the past EPS estimates
for Hyloris Pharmaceuticals SA?

What are the EBIT projections
for Hyloris Pharmaceuticals SA?

How accurate were the past EBIT estimates
for Hyloris Pharmaceuticals SA?

Compare the revenue forecasts
for Hyloris Pharmaceuticals SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Hyloris Pharmaceuticals SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Hyloris Pharmaceuticals SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Hyloris Pharmaceuticals SA compared to its peers.

Compare the P/E ratios
of Hyloris Pharmaceuticals SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Hyloris Pharmaceuticals SA with its peers.

Analyze the financial leverage
of Hyloris Pharmaceuticals SA compared to its main competitors.

Show all profitability ratios
for Hyloris Pharmaceuticals SA.

Provide ROE
for Hyloris Pharmaceuticals SA.

Provide ROA
for Hyloris Pharmaceuticals SA.

Provide ROIC
for Hyloris Pharmaceuticals SA.

Provide ROCE
for Hyloris Pharmaceuticals SA.

Provide Gross Margin
for Hyloris Pharmaceuticals SA.

Provide Operating Margin
for Hyloris Pharmaceuticals SA.

Provide Net Margin
for Hyloris Pharmaceuticals SA.

Provide FCF Margin
for Hyloris Pharmaceuticals SA.

Show all solvency ratios
for Hyloris Pharmaceuticals SA.

Provide D/E Ratio
for Hyloris Pharmaceuticals SA.

Provide D/A Ratio
for Hyloris Pharmaceuticals SA.

Provide Interest Coverage Ratio
for Hyloris Pharmaceuticals SA.

Provide Altman Z-Score Ratio
for Hyloris Pharmaceuticals SA.

Provide Quick Ratio
for Hyloris Pharmaceuticals SA.

Provide Current Ratio
for Hyloris Pharmaceuticals SA.

Provide Cash Ratio
for Hyloris Pharmaceuticals SA.

What is the historical Revenue growth
over the last 5 years for Hyloris Pharmaceuticals SA?

What is the historical Net Income growth
over the last 5 years for Hyloris Pharmaceuticals SA?

What is the current Free Cash Flow
of Hyloris Pharmaceuticals SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Hyloris Pharmaceuticals SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Hyloris Pharmaceuticals SA

Balance Sheet Decomposition
Hyloris Pharmaceuticals SA

Current Assets 35.3m
Cash & Short-Term Investments 30.7m
Receivables 3.8m
Other Current Assets 804k
Non-Current Assets 12.4m
Long-Term Investments 4.8m
PP&E 2.2m
Intangibles 3.8m
Other Non-Current Assets 1.6m
Current Liabilities 6.8m
Accounts Payable 3.3m
Other Current Liabilities 3.4m
Non-Current Liabilities 1.9m
Long-Term Debt 1.5m
Other Non-Current Liabilities 343k
Efficiency

Earnings Waterfall
Hyloris Pharmaceuticals SA

Revenue
2.1m EUR
Cost of Revenue
-93k EUR
Gross Profit
2m EUR
Operating Expenses
-17.8m EUR
Operating Income
-15.8m EUR
Other Expenses
466k EUR
Net Income
-15.4m EUR

Free Cash Flow Analysis
Hyloris Pharmaceuticals SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

HYL Profitability Score
Profitability Due Diligence

Hyloris Pharmaceuticals SA's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
29/100
Profitability
Score

Hyloris Pharmaceuticals SA's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

HYL Solvency Score
Solvency Due Diligence

Hyloris Pharmaceuticals SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Hyloris Pharmaceuticals SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HYL Price Targets Summary
Hyloris Pharmaceuticals SA

Wall Street analysts forecast HYL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HYL is 12.99 EUR with a low forecast of 5.05 EUR and a high forecast of 18.06 EUR.

Lowest
Price Target
5.05 EUR
18% Upside
Average
Price Target
12.99 EUR
203% Upside
Highest
Price Target
18.06 EUR
321% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HYL?

Click here to dive deeper.

Dividends

Hyloris Pharmaceuticals SA
does not pay dividends
Shareholder Yield

Current shareholder yield for HYL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA

Country

Belgium

Industry

Pharmaceuticals

Market Cap

123.8m EUR

Dividend Yield

0%

Description

Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 14 full-time employees. The company went IPO on 2020-06-29. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.

Contact

LIEGE
Liege
Boulevard Gustave Kleyer 17
+3243460207
hyloris.com

IPO

2020-06-29

Employees

14

Officers

Co-Founder, CEO & Director
Mr. Stijn Van Rompay
Co-Founder, Chief Business Development Officer & Executive Director
Mr. Thomas Jacobsen
Chief Financial Officer
Mr. Jean-Luc Vandebroek
Chief Operating Officer
Dr. Dietmar Aichhorn Ph.D.
Investor Relations Manager & Communications manager
Mr. Sven Watthy
Chief Legal Officer
Mr. Koenraad Van Der Elst

See Also

Discover More
What is the Intrinsic Value of one HYL stock?

The intrinsic value of one HYL stock under the Base Case scenario is 4.37 EUR.

Is HYL stock undervalued or overvalued?

Compared to the current market price of 4.29 EUR, Hyloris Pharmaceuticals SA is Undervalued by 2%.

Back to Top